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OBJECTIVES: To assess and compare costs and effects of Mircera vs. Aranesp treat-
ment of pre-dialysis patients. METHODS: A systematic review of medical data bases 
according to EBM principles was conducted. Efﬁcacy and safety data for both treat-
ment options were compared. No signiﬁcant differences in clinical efﬁcacy and safety 
of both treatments were identiﬁed. Cost-minimization analysis was conducted in order 
to compare costs. The analysis was performed from the perspective of public payer in 
a two-year time horizon. Only direct cost data, gathered in three reference centers in 
Poland, were taken into account (drug’s costs, drug administration and adverse events 
costs). According to Polish HTA Agency guidelines costs were discounted by 5%. 
Dosing schemes for both drugs were assumed based on the assumptions of the 
National Health Fund Therapeutic Area Program for the CKD patients in pre-dialysis 
period: Mircera- 50 Mg s.c.(mean monthly dose), Aranesp: 10 Mg once weekly, or 
20 Mg—once per 2 weeks or 40 Mg once monthly i.v. or s.c (mean dosing was calcu-
lated). Sensitivity analysis was done to test the robustness of the results. Results were 
tested for changes in the value of accounting points deﬁned by the payer (/20%), 
discounting rate for costs and changes in drug dosing. RESULTS: CMA showed 
savings of 1 194 PLN (1 EUR  4.55 PLN) per patient with Mircera treatment vs. 
Aranesp in the 2 year horizon. Savings were due to the once monthly Mircera admin-
istration scheme. Results of the basic analysis were conﬁrmed by the sensitivity analy-
sis. CONCLUSIONS: Mircera treatment of CKD patients in pre-dialysis period is as 
effective and safe as Aranesp therapy, but offers savings to the public payer.
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OBJECTIVES: End Stage Renal Disease (ESRD) is associated with high health care           
costs and low quality of life (QoL) compared to Chronic Kidney Disease (CKD). The 
renoprotective effectiveness of ACE inhibitors (ACEi) is largely determined by the ACE 
insertion deletion (I/D) polymorphism. We determined the cost-effectiveness of ACEi 
therapy in non-diabetic nephropathy for the ACE II/ID and for the ACE DD genotype. 
Furthermore, we considered a selective screen-and-treat strategy where patients are 
prescriped alternative therapy based on their ACE (I/D) polymorphism. METHODS: 
Time-dependent Markov models were constructed; cohorts of 1000 patients were 
followed for 10 years. Data were mainly gathered from the Ramipril Efﬁcacy In 
Nephropathy (REIN) trial. Both univariate and probabilistic sensitivity analyses were 
performed. RESULTS: ACEi therapy compared to placebo both reduces costs and         
improves QALY’s more in the ACE DD group (a105,104 and 0.553 QALYs gained 
per patient) than in the ACE II/ID group (a15,826 and 0.091 QALYs gained). 
Sensitivity analyses demonstrated a 30.2% probability of ACEi therapy being not 
cost-effective in the ACE II/ID group, against an almost 100% probability of cost-
effectiveness in the ACE DD group. Cost of dialysis had the largest inﬂuence on the 
cost-effectiveness. An alternative treatment for patients with the ACE II/ID genotype, 
incorporated in a selective screen-and-treat strategy, should feature a 9.1% increase 
in survival time for the strategy to be cost-effective. High alternative treatment 
effectiveness and dialysis costs improve the cost-effectiveness of a screening strategy. 
CONCLUSIONS: ACEi therapy is a cost saving treatment in non diabetic nephropathy,           
irrespectively of ACE (I/D) genotype. However, ACEi therapy saved more costs and 
more health gaines were achieved in the ACE DD genotype than in the ACE II/ID 
genotype. An alternative treatment featuring a modest increase in survival time for 
patients with the ACE II/ID genotype can be incorporated in a cost-effective screen-
and-treat strategy.
URINARY/KIDNEY DISORDERS – Patient-Reported Outcomes Studies
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OBJECTIVES: To develop and validate a brief questionnaire to evaluate the effects 
of gastrointestinal (GI) symptoms on HRQoL in solid-organ transplant recipients. 
METHODS: Two phases study: 1)Development of pilot version of questionnaire 
(SIGIT-QOL): bibliography review, list of areas and items included in the question-
naire, panels of 8 experts and 50 patients and questionnaire modiﬁcation to reach 
consensus and ﬁnal version, and 2)Questionnaire validation: multicenter (34 centers) 
observational 6 weeks study in solid-organ transplant recipients (kidney, liver, heart 
and lung) 3 to 12 weeks post-transplantation. Patients responded to the new question-
naire and to the GastroIntestinal Quality of Life Index-GIQLI; age, sex, transplant 
date, acute rejection and GI symptoms evaluated by physicians were registered. Psy-
chometric properties of SIGIT-QOL questionnaire (feasibility, content, construct and 
convergent validity and reliability) were evaluated. RESULTS: The ﬁrst phase gener-
ated a questionnaire of 17 items. 274 patients participated in second phase: mean age 
52.7(7.59)years, 66.3%males. Mean time from transplant 6.7(3.1) months, 44(16.4%) 
patients presented acute rejection and 44.4% GI symptoms. 95.5% patients responded 
to all items of SIGIT-QOL in 6.37(5.6) minutes vs 12.12(11.83) minutes of GIQLI. 
According to factorial analysis, all items were grouped in one dimension with a reli-
ability (Cronbach’s alpha) of 0.88. Mean score was 57.80(9.8) (theoretical range: 
0–68). A moderate, positive signiﬁcant correlation with GIQLI (r  0.67), and 
a mild negative correlation with physician’s evaluation of GI symptoms, were found. 
CONCLUSIONS: A new 17-items questionnaire SIGIT-QOL has been developed; it 
shows good feasibility, validity and reliability to evaluate the effects of gastroin- 
testinal symptoms on health related-QoL in solid-organ transplant recipients with a 
functioning graft.
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OBJECTIVES: The National Institutes of Diabetes and Digestive and Kidney Diseases 
(NIDDK) requires cystoscopic features of interstitial cystitis (IC) as a diagnostic crite-
rion, yet this excludes signiﬁcant numbers of patients with clinical symptoms of IC/
Painful Bladder Syndrome (PBS). Patient-reported, symptom-based measures may be 
more appropriate for identifying IC/PBS patients. Existing measures have poor speci-
ﬁcity, likely due to inadequate content validity. The objective was to conduct qualita-
tive interviews with patients to identify key IC symptoms, and the language used to 
describe them, to develop a new symptom-based IC screener. METHODS: A total of 
44 IC/PBS patients with a conﬁrmed diagnosis in the US, France and Germany (aged 
22–72) were interviewed about their symptoms and subsequent impact on quality 
of life. Ten US overactive bladder (OAB) patients (aged 31–69), a condition often 
confused with IC, were also interviewed to improve speciﬁcity. Interviews included 
open-ended questions, creative tasks and focussed discussion. Thematic analysis was 
conducted utilising grounded theory methods. RESULTS: Key symptoms identiﬁed by 
IC/PBS patients were the urge to urinate, urination frequency, and pain. Urge had four 
components: 1) need to urinate driven by pain; 2) a need to urinate to avoid pain 
getting worse; 3) a constant need to urinate and; 4) a sudden need to urinate. In 
 contrast, OAB patients reported urge that did not involve pain. Both OAB and IC/PBS 
patients experienced high day and night-time urination frequency. IC pain was per-
ceived to be in the bladder, abdomen or pelvis, and was most commonly described as 
“pressure”, “burning”, “sharp” and “discomfort”. The screener items were developed 
using these data, with guidance from IC experts. CONCLUSIONS: Utilising an exten-
sive, geographically diverse interview process, we elicited key symptoms that differenti-
ate IC/PBS from OAB patients. Efforts to optimize the sensitivity and speciﬁcity of the 
new screener are critical to accurately identify patients with IC/PBS.
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OBJECTIVES: A French epidemiological study found that 19% of women aged 18–70           
years could be classiﬁed as having stress urinary incontinence (SUI). Our study 
explores SUI women’s willingness to seek medical treatment and their preferences 
relative to different therapeutic options. METHODS: A telephone survey was con-    
ducted among 1000 women aged 18–70 with SUI. Women willing to be treated were 
asked about their preferences between perineo-sphincter exercises, TVT surgery and 
an oral medication. A simple conjoint analysis was conducted in order to explore the 
structure of preferences between surgery and medication conditional to the probability 
of success and the out-of-the-pocket cost of therapies. Preferences about exercises were 
not assessed any further since the results of a pilot study indicated that most women 
would tend to try this therapy before any of the others. RESULTS: Fifty-ﬁve percent 
of the women are willing to try medication or surgery in the next six months. 92% 
of these women gave consistent answers in the conjoint analysis exercise. They are 
more concerned with the nature of the treatment (importance weight of 40%) than 
with having to pay a45 to try it (importance weight of 29%). According to this analy-
sis, it is predicted that 71% of these women would prefer a surgery with 95% chance 
of success and reimbursed to a medication with 60% chance of success and costing 
a45 the trial. However, when asked directly about their preferences, the estimations 
